+117.7%
ASTS vs MRNA
-25.9%
+143.5%
-85.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -7.6% | -4.8% | -2.8% | -6.9% |
| 7D | -30.4% | -20.9% | -9.5% | -28.0% |
| 30D | -39.1% | -13.3% | -25.9% | -37.9% |
| 3M | -62.0% | +212.6% | -274.6% | -71.9% |
| 6M | -70.6% | +309.0% | -379.7% | -80.3% |
| YTD | -64.9% | +567.3% | -632.2% | -80.2% |
| 1Y | -56.2% | +689.7% | -745.9% | -76.5% |
| 3Y | +427.7% | +157.4% | +270.3% | +255.0% |
| All | +117.7% | -25.9% | +143.5% | +75.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling